Document:

<PAGE>

                                                                     Exhibit 4.4

                                 NEUROCHEM INC.

                             MATERIAL CHANGE REPORT
                             ----------------------

1.   NAME AND ADDRESS OF ISSUER

Neurochem Inc. (the "NEUROCHEM")
275 Armand-Frappier Blvd.
Laval, QC  H7V 4A7

2.   DATE OF MATERIAL CHANGE

January 20, 2005

3.   NEWS RELEASE

A press release was issued on January 20, 2005 by Neurochem in Laval, Quebec.

4.   SUMMARY OF MATERIAL CHANGE

On January 20, 2005, Neurochem announced senior management appointments and
reassignments of responsibility.

5.   FULL DESCRIPTION OF MATERIAL CHANGE

On January 20, 2005, Neurochem announced the renewed commitment by Francesco
Bellini, Chairman and CEO, to remain with the Company in an executive capacity
for at least three more years. Dr. Bellini also assumes the office of President.
This commitment was evidenced by the three year renewal of the management
services agreement between Neurochem and Picchio International Inc., by virtue
of which the services of Francesco Bellini are provided to Neurochem. At the
same time, Neurochem announced the appointment of two new members to its senior
management team as well as other changes at the senior management level.

Joining Neurochem are Shona McDiarmid, PhD, Vice President - Intellectual
Property, and Daniel Delorme, PhD, as Vice President - Research. Philippe
Calais, Pharm. D., currently President, is appointed President - Global
Business, and Denis Garceau, PhD, Vice President - Drug Development, becomes
Senior Vice President, Drug Development. Francine Gervais, PhD, Vice President,
Research and Development, will be leaving Neurochem but will remain a consultant
to Neurochem.

Dr. Shona McDiarmid is a lawyer who brings to Neurochem more than fifteen years
experience securing and defending intellectual property rights in the
pharmaceutical, medical and biotechnology fields. Dr. McDiarmid began her career
in intellectual property at Bereskin & Parr in Toronto, where she practiced
intellectual property law with a focus on biotechnology and pharmaceutical
patents and related litigation. In 1996 she joined BioChem Pharma as Director of
Intellectual Property, where she managed an extensive international patent
portfolio in core fields, including CNS, antivirals, anti-infectives, oncology,
biologics and vaccines. Following the merger of BioChem Pharma with Shire
Pharmaceuticals Group in 2001, Dr. McDiarmid was

<PAGE>
                                      -2-

promoted to Vice President of Global Intellectual Property for the Shire
Pharmaceuticals Group. Dr. McDiarmid holds a PhD in biology from the University
of Western Ontario, and a law degree from the University of Ottawa. Dr.
McDiarmid is also a member of the Ontario Bar and a registered Canadian patent
agent.

Dr. Daniel Delorme has almost 20 years experience in biotechnology and
pharmaceutical companies. Prior to joining Neurochem, he served between 2003 and
2005 as Vice President, Research and Development, at the Canadian
biopharmaceutical company Phagetech Inc. and from 1998 to 2003, Dr. Delorme was
Vice President Medicinal Chemistry at MethylGene Inc. From 1995 to 1998, Dr.
Delorme served as Associate Director at AstraZeneca, Montreal, and prior to that
as a Research Fellow at Merck-Frosst. He is the co-inventor of 33 US patents and
patent applications and the author of 42 scientific papers. Dr. Delorme received
his doctoral degree in Organic Chemistry from the Universite de Montreal.

The responsibilities of Dr. Calais as President, Global Business, will encompass
the establishment of Neurochem's international marketing and sales operations in
North America and Europe and the management of collaborative activities with
business partners.

With his nomination, Dr. Garceau will be adding to his current role in drug
development, a more active participation in determining Neurochem's strategic
scientific direction.

6.   CONFIDENTIALITY

Not applicable.

7.   OMITTED INFORMATION

None.

8.   EXECUTIVE OFFICER

For further information, please contact Lise Hebert, Vice-President, Corporate
Communications, at (450) 680-4572.

DATED this 27th day of January, 2005.

                                      NEUROCHEM INC.

                                      (signed) Lise Hebert
                                      ------------------------------------------
                                  By: Lise Hebert,
                                      Vice-President, Corporation CommunicationsEX-10.1

Exhibit 10.1

ARBITRON INC. 1999 STOCK INCENTIVE PLAN

NON-QUALIFIED STOCK OPTION AGREEMENT

THIS AGREEMENT is entered into and effective as of           , 20     (the “Date of Grant”),
by and between Arbitron Inc. (the “Company”) and [Name] (the “Optionee”).

A. The Company has adopted the Arbitron Inc. 1999 Stock Incentive Plan (as may be amended or
supplemented, the “Plan”) authorizing the Board of Directors of the Company, or a committee as
provided for in the Plan (the Board or such a committee to be referred to as the “Committee”), to
grant stock options to employees of the Company and its Subsidiaries (as defined in the Plan).

B. The Company desires to give the Optionee an inducement to acquire a proprietary interest in
the Company and an added incentive to advance the interests of the Company by granting to the
Optionee an option to purchase shares of common stock of the Company pursuant to the Plan.

Accordingly, the parties agree as follows:

1. Grant of Option.

The Company hereby grants to the Optionee the right, privilege and option (the “Option”) to
purchase [Shares] shares (the “Option Shares”) of the Company’s common stock, $0.50 par value (the
“Common Stock”), according to the terms and subject to the conditions hereinafter set forth and as
set forth in the Plan. The Option granted hereunder shall not be an incentive stock option within
the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”).

2. Option Exercise Price.

The per share price to be paid by Optionee in the event of an exercise of the Option will be
$     .

3. Duration of Option and Time of Exercise.

3.1 Initial Period of Exercisability. Except as provided in Sections 3.2 and 3.3
hereof, the Option shall become exercisable with respect to one-third of the Option Shares on each
of the first, second and third anniversaries of the Date of Grant. The foregoing rights to
exercise the Option will be cumulative with respect to the Option Shares becoming exercisable on
each such date, but in no event will the Option be exercisable after, and the Option will become
void and expire as to all unexercised Option Shares at, 5:00 p.m. (Eastern Standard Time) on the
tenth anniversary of the Date of Grant (the “Time of Option Termination”).

3.2 Termination of Employment.

(a) Termination Due to Death, Disability or Retirement. In the event the
Optionee’s employment with the Company and all Subsidiaries is terminated by reason of
death, Disability (as defined in the Plan) or Retirement (as defined in the Plan), the
Option will become immediately exercisable in full and remain exercisable until the Time of
Option Termination.

(b) Termination for Reasons Other Than Death, Disability or Retirement. In the
event that the Optionee’s employment with the Company and all Subsidiaries is terminated for
any reason other than death, Disability or Retirement, or the Optionee is in the employ of a
Subsidiary and the Subsidiary ceases to be a Subsidiary of the Company (unless the Optionee
continues in the employ of the Company or another Subsidiary), all rights of the Optionee
under the Plan and this Agreement will immediately terminate without notice of any kind, and
the Option will no longer be exercisable; provided, however, that, if such termination is
due to any reason other than termination by the Company or any Subsidiary for Cause (as
defined in Section 9 of this Agreement), the Option will remain exercisable to the extent
exercisable as of such termination for a period of three months after such termination (but
in no event after the Time of Option Termination).

3.3 Change in Control.

(a) Impact of Change in Control. If a Change in Control (as defined in Section
9 of this Agreement) of the Company occurs, and the Option has been outstanding for at least
two months, the Option will become immediately exercisable in full and will remain
exercisable until the Time of Option Termination, regardless of whether the Optionee remains
in the employ of the Company or any Subsidiary. In addition, if a Change in Control of the
Company occurs, the Committee, in its sole discretion and without the consent of the
Optionee, may determine that the Optionee will receive, with respect to some or all of the
Option Shares, as of the effective date of any such Change in Control of the Company, cash
in an amount equal to the excess of the Fair Market Value (as defined in the Plan) of such
Option Shares immediately prior to the effective date of such Change in Control of the
Company over the option exercise price per share of the Option.

(b) Authority to Modify Change of Control Provisions. Prior to a Change of
Control, the Optionee will have no rights under this Section 3.3, and the Committee will
have the authority, in its sole discretion, to rescind, modify or amend this Section 3.3
without the consent of the Optionee.

4. Manner of Option Exercise.

4.1 Notice. This Option may be exercised by the Optionee in whole or in part from
time to time, subject to the conditions contained in the Plan and in this Agreement, by delivery,
in person, by facsimile or electronic transmission or through the mail, to the Company at its
principal executive office in New York, New York (Attention: Corporate Secretary), of a written
notice of exercise. Such notice must be in a form satisfactory to the Committee, must identify the
Option, must specify the number of Option Shares with respect to which the Option is being
exercised, and must be signed by the person or persons so exercising the Option. Such notice must
be accompanied by payment in full of the total exercise price for the Option Shares to be
purchased. In the event that the Option is being exercised, as provided by the Plan and Section
3.2 of this Agreement, by any person or persons other than the Optionee, the notice must be
accompanied by appropriate proof of right of such person or persons to exercise the Option. If the
Optionee retains the Option Shares purchased, as soon as practicable after the effective exercise
of the Option, the Optionee will be recorded on the stock transfer books of the Company as the
owner of the Option Shares purchased, and the Company will deliver to the Optionee one or more duly
issued stock certificates evidencing such ownership.

4.2 Payment. At the time of exercise of the Option, the Optionee must pay the total
exercise price of the Option Shares to be purchased entirely in cash (including a check, bank draft
or money order, payable to the order of the Company); provided, however, that the Committee, in its
sole discretion and upon terms and conditions established by the Committee, may allow such payment
to be made, in whole or in part, by tender of a full recourse promissory note or a Broker Exercise
Notice (as such terms are defined in the Plan), or by a combination of such methods.

5. Rights and Restrictions of Optionee; Transferability.

5.1 Employment. Nothing in this Agreement will interfere with or limit in any way the
right of the Company or any Subsidiary to terminate the employment of the Optionee at any time, nor
confer upon the Optionee any right to continue in the employ of the Company or any Subsidiary at
any particular position or rate of pay or for any particular period of time.

5.2 Rights as a Stockholder. The Optionee will have no rights as a stockholder unless
and until all conditions to the effective exercise of the Option (including, without limitation,
the conditions set forth in Sections 4 and 6 of this Agreement) have been satisfied and the
Optionee has become the holder of record of such shares. No adjustment will be made for dividends
or distributions with respect to the Option Shares as to which there is a record date preceding the
date the Optionee becomes the holder of record of such Option Shares, except as may otherwise be
provided in the Plan or determined by the Committee in its sole discretion.

5.3 Restrictions on Transfer. Except pursuant to testamentary will or the laws of
descent and distribution or as otherwise expressly permitted by the Plan, no right or interest of
the Optionee in the Option prior to exercise may be assigned or transferred, or subjected to any
lien, during the lifetime of the Optionee, either voluntarily or involuntarily, directly or
indirectly, by operation of law or otherwise. The Optionee will, however, subject to applicable
laws be entitled to designate a beneficiary to receive the Option upon such Optionee’s death in the
manner provided by the Plan, and, in the event of the Optionee’s death, exercise of the Option (to
the extent permitted pursuant to Section 3.2(a) of this Agreement) may be made by the Optionee’s
designated beneficiary.

5.4 Restrictions Regarding Employment.

(a) The Optionee agrees that he or she will not take any Adverse Actions (as defined
below) against the Company or any Subsidiary at any time during the period that the Option
is or may yet become exercisable in whole or in part or at any time before one year
following the Optionee’s termination of employment with the Company or any Subsidiary,
whichever is later (the “Restricted Period”). The Optionee acknowledges that damages which
may arise from a breach of this Section 5.4 may be impossible to ascertain or prove with
certainty. Notwithstanding anything in this Agreement or the Plan to the contrary, in the
event that the Company determines in its sole discretion that the Optionee has taken Adverse
Actions against the Company or any Subsidiary at any time during the Restricted Period, in
addition to other legal remedies which may be available, (i) the Company will be entitled to
an immediate injunction from a court of competent jurisdiction to end such Adverse Action,
without further proof of damage, (ii) the Committee will have the authority in its sole
discretion to terminate immediately all rights of the Optionee under the Plan and this
Agreement without notice of any kind, and (iii) the Committee will have the authority in its
sole discretion to rescind the exercise of all or any portion of the Option to the extent
that such exercise occurred within six months prior to the date the Optionee first commences
any such Adverse Actions and require the Optionee to disgorge any profits (however defined
by the Committee) realized by the Optionee relating to such exercised portion of the Option
or any Option Shares issued or issuable upon such exercise. Such disgorged profits paid to
the Company must be made in cash (including check, bank draft or money order) or, with the
Committee’s consent, shares of Common Stock with a Fair Market Value on the date of payment
equal to the amount of such payment. The Company will be entitled to withhold and deduct
from future wages of the Optionee (or from other amounts that may be due and owing to the
Optionee from the Company or a Subsidiary) or make other arrangements for the collection of
all amounts necessary to satisfy such payment obligation.

(b) For purposes of this Agreement, an “Adverse Action” will mean any of the following:
(i) engaging in any commercial activity in competition with any part of the business of the
Company or any Subsidiary as conducted during the Restricted Period for which the Optionee
has or had access to trade secrets and/or confidential information; (ii) diverting or
attempting to divert from the Company or any Subsidiary any business of any kind, including,
without limitation, interference with any business relationships with suppliers, customers,
licensees, licensors, clients or contractors; (iii) participate in the ownership, operation
or control of, be employed by, or connected in any manner with any person or entity which
solicits, offers or provides any services or products similar to those which the Company or
any Subsidiary offers to its customers or prospective customers, (iv) making, or causing or
attempting to cause any other person or entity to make, any statement, either written or
oral, or convey any information about the Company or any Subsidiary that is disparaging or
that in any way reflects negatively on the Company or any Subsidiary; or (v) engaging in any
other activity that is hostile, contrary or harmful to the interests of the Company or any
Subsidiary, including, without limitation, influencing or advising any person who is
employed by or in the service of the Company or any Subsidiary to leave such employment or
service to compete with the Company or any Subsidiary or to enter into the employment or
service of any actual or prospective competitor of the Company or any Subsidiary,
influencing or advising any competitor of the Company or any Subsidiary to employ to
otherwise engage the services of any person who is employed by or in the service of the
Company or any Subsidiary, or improperly disclosing or otherwise misusing any trade secrets
or confidential information regarding the Company or any Subsidiary.

(c) Should any provision of this Section 5.4 of the Agreement be held invalid or
illegal, such illegality shall not invalidate the whole of this Section 5.4 of the
Agreement, but, rather, the Agreement shall be construed as if it did not contain the
illegal part or narrowed to permit its enforcement, and the rights and obligations of the
parties shall be construed and enforced accordingly. In furtherance of and not in limitation
of the foregoing, the Optionee expressly agrees that should the duration of or geographical
extent of, or business activities covered by, any provision of this Agreement be in excess
of that which is valid or enforceable under applicable law, then such provision shall be
construed to cover only that duration, extent or activities that may validly or enforceably
be covered. The Optionee acknowledges the uncertainty of the law in this respect and
expressly stipulates that this Agreement shall be construed in a manner that renders its
provisions valid and enforceable to the maximum extent (not exceeding its express terms)
possible under applicable law. This Section 5.4 of the Agreement does not replace and is in
addition to any other agreements the Optionee may have with the Company or any of its
Subsidiaries on the matters addressed herein.

6. Securities Law and Other Restrictions.

Notwithstanding any other provision of the Plan or this Agreement, the Company will not be
required to issue, and the Optionee may not sell, assign, transfer or otherwise dispose of, any
Option Shares, unless (a) there is in effect with respect to the Option Shares a registration
statement under the Securities Act of 1933, as amended, and any applicable state or foreign
securities laws or an exemption from such registration, and (b) there has been obtained any other
consent, approval or permit from any other regulatory body which the Committee, in its sole
discretion, deems necessary or advisable. The Company may condition such issuance, sale or
transfer upon the receipt of any representations or agreements from the parties involved, and the
placement of any legends on certificates representing Option Shares, as may be deemed necessary or
advisable by the Company in order to comply with such securities law or other restrictions.

7. Withholding Taxes.

The Company is entitled to (a) withhold and deduct from future wages of the Optionee (or from
other amounts that may be due and owing to the Optionee from the Company), or make other
arrangements for the collection of, all legally required amounts necessary to satisfy any federal
or provincial withholding tax requirements attributable to the Option, or (b) require the Optionee
promptly to remit the amount of such withholding to the Company before acting on the Optionee’s
notice of exercise of the Option. In the event that the Company is unable to withhold such
amounts, for whatever reason, the Optionee agrees to pay to the Company an amount equal to the
amount the Company would otherwise be required to withhold under federal, state or local law.

8. Adjustments.

In the event of any reorganization, merger, consolidation, recapitalization, liquidation,
reclassification, stock dividend, stock split, combination of shares, rights offering, divestiture
or extraordinary dividend (including a spin-off), or any other change in the corporate structure or
shares of the Company, the Committee (or, if the Company is not the surviving corporation in any
such transaction, the board of directors of the surviving corporation), in order to prevent
dilution or enlargement of the rights of the Optionee, will make appropriate adjustment (which
determination will be conclusive) as to the number and kind of securities or other property
(including cash) subject to, and the exercise price of, the Option.

9. Certain Definitions. For purposes of this Agreement, the following additional
definitions will apply:

(a) “Benefit Plan” means any formal or informal plan, program or other arrangement
heretofore or hereafter adopted by the Company or any Subsidiary for the direct or indirect
provision of compensation to the Optionee (including groups or classes of participants or
beneficiaries of which the Optionee is a member), whether or not such compensation is
deferred, is in the form of cash or other property or rights, or is in the form of a benefit
to or for the Optionee.

(b) “Cause” will have the meaning set forth in any employment or other agreement or
policy applicable to the Optionee or, if no such agreement or policy exists, will mean (i)
dishonesty, fraud, misrepresentation, theft, embezzlement or injury or attempted injury, in
each case related to the Company or any Subsidiary, (ii) any unlawful or criminal activity
of a serious nature, (iii) any breach of duty, habitual neglect of duty or unreasonable job
performance, or (iv) any material breach of any employment, service, confidentiality or
noncompete agreement entered into with the Company or any Subsidiary.

(c) “Change of Control” will have the meaning set forth in the Plan plus such other
event or transaction as the Board shall determine constitutes a Change of Control, or such
other meaning as may be adopted by the Committee from time to time in its sole discretion.

10. Subject to Plan.

The Option and the Option Shares granted and issued pursuant to this Agreement have been
granted and issued under, and are subject to the terms of, the Plan. The terms of the Plan are
incorporated by reference in this Agreement in their entirety, and the Optionee, by execution of
this Agreement, acknowledges having received a copy of the Plan. The provisions of this Agreement
will be interpreted as to be consistent with the Plan, and any ambiguities in this Agreement will
be interpreted by reference to the Plan. In the event that any provision of this Agreement is
inconsistent with the terms of the Plan, the terms of the Plan will prevail.

11. Miscellaneous.

11.1 Binding Effect. This Agreement will be binding upon the heirs, executors,
administrators and successors of the parties to this Agreement.

11.2 Governing Law. This Agreement and all rights and obligations under this
Agreement will be construed in accordance with the Plan and governed by the laws of the State of
Delaware, without regard to conflicts or choice of law rule or principle that might otherwise refer
construction or interpretation of this Agreement to the substantive laws of another jurisdiction.

11.3 Entire Agreement. This Agreement and the Plan set forth the entire agreement and
understanding of the parties to this Agreement with respect to the grant and exercise of the Option
and the administration of the Plan and supersede all prior agreements, arrangements, plans and
understandings relating to the grant and exercise of the Option and the administration of the Plan.

11.4 Amendment and Waiver. Other than as provided in the Plan, this Agreement may be
amended, waived, modified or canceled only by a written instrument executed by the parties to this
Agreement or, in the case of a waiver, by the party waiving compliance.

1

The parties to this Agreement have executed this Agreement effective the day and year first
above written.

ARBITRON INC.

By

Name

Title

	 	 	 
	By execution of this Agreement,

the Optionee acknowledges having

received a copy of the Plan.

	 	OPTIONEE

	
 
	 	 
	 
	 	 
	
 
	 	Print Name:
	 
	 	 
	
 
	 	Address:
	
 
	 	 

Social Security Number:

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}]]